Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer.
Loriot Y, Kamal M, Syx L, Nicolle R, Dupain C, Menssouri N, Duquesne I, Lavaud P, Nicotra C, Ngocamus M, Lacroix L, Tselikas L, Crehange G, Friboulet L, Castel-Ajgal Z, Neuzillet Y, Borcoman E, Beuzeboc P, Marret G, Gutman T, Wong J, Radvanyi F, Dureau S, Scoazec JY, Servant N, Allory Y, Besse B, Andre F, Le Tourneau C, Massard C, Bieche I. Loriot Y, et al. Among authors: lavaud p. Nat Commun. 2024 Oct 30;15(1):9370. doi: 10.1038/s41467-024-53775-4. Nat Commun. 2024. PMID: 39478018 Free PMC article. No abstract available.
Atezolizumab in urothelial bladder carcinoma.
Hamilou Z, Lavaud P, Loriot Y. Hamilou Z, et al. Among authors: lavaud p. Future Oncol. 2018 Feb;14(4):331-341. doi: 10.2217/fon-2017-0433. Epub 2017 Nov 14. Future Oncol. 2018. PMID: 29135284 Review.
Durvalumab in urothelial cancers.
Lavaud P, Hamilou Z, Loriot Y, Massard C. Lavaud P, et al. Expert Rev Anticancer Ther. 2018 Apr;18(4):311-318. doi: 10.1080/14737140.2018.1443812. Epub 2018 Mar 5. Expert Rev Anticancer Ther. 2018. PMID: 29486607 Review.
Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
Gravis G, Billon E, Baldini C, Massard C, Hilgers W, Delva R, Walz J, Pignot G, Rybikowski S, Dermeche S, Thomassin J, Brunelle S, Lavaud P, Loriot Y; French Genito-Urinary Tumor Group (GETUG). Gravis G, et al. Among authors: lavaud p. Eur J Cancer. 2018 Nov;104:236-238. doi: 10.1016/j.ejca.2018.09.002. Epub 2018 Oct 11. Eur J Cancer. 2018. PMID: 30316610 No abstract available.
Focus on Recommendations for the Management of Non-small Cell Lung Cancer.
Lavaud P, Besse B, de Baere T, Deschamps F, Mussot S, Le Pechoux C, Caramella C, Mercier O, Mezquitta L, Botticella A, Pradere P, Adam J, Planchard D, Tselikas L. Lavaud P, et al. Cardiovasc Intervent Radiol. 2019 Sep;42(9):1230-1239. doi: 10.1007/s00270-019-02222-9. Epub 2019 May 6. Cardiovasc Intervent Radiol. 2019. PMID: 31062067 No abstract available.
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L. Recondo G, et al. Among authors: lavaud p. Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4. Clin Cancer Res. 2020. PMID: 31585938 Free PMC article.
89 results